Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356265 | 1.00 | PPARA (0.58) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL1731144 | 1.00 | PPARA (0.58) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL12305797 | 0.90 | PPARA (0.56) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL5639231 | 0.90 | PPARA (0.56) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL3873538 | 0.90 | PPARA (0.56) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL6318882 | 0.90 | SYK (0.58) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL18256464 | 0.90 | SYK (0.58) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL2869086 | 0.89 | PPARA (0.55) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL2869084 | 0.89 | PPARA (0.55) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL1561964 | 0.88 | PPARA (0.59) | PPARASYKCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM LTD (IL) | 2022-11-17 | — | — | US | disclosed |
| WO-2022191338-A1 | LEVODOPA-PRODRUGS AND CARBIDOPA-PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-09-15 | — | — | WO | disclosed |
| EP-4025200-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2022-07-13 | — | — | EP | disclosed |
| CN-114727973-A | Liquid compositions comprising L-dopa amino acid conjugates and uses thereof | 纽罗德姆有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | disclosed |
| EP-2341049-A1 | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors | Novartis AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | NOVARTIS AG (CH) | 2008-06-12 | — | — | US | disclosed |
| CN-100364974-C | Method for synthesis of (2s,3as,7as)-perhydroindole-2- carboxylic acid and esters thereof, and use in the synthesis of perindopril | SERVIER LAB (FR) | 2008-01-30 | — | — | CN | disclosed |
| CN-1753906-A | Process for the synthesis of perindopril and its pharmaceutically acceptable salts | SERVIER LAB (FR) | 2006-03-29 | — | — | CN | disclosed |
| CN-1753869-A | Method for synthesis of (2s,3as,7as)-perhydroindole-2- carboxylic acid and esters thereof, and use in the synthesis of perindopril | SERVIER LAB (FR) | 2006-03-29 | — | — | CN | disclosed |
| CN-1753907-A | Method for synthesis of (2s,3as,7as)-1-((s)-alanyl)-octahydro-1h-indole-2-carboxylic acid derivatives and use in the synthesis of perindopril | SERVIER COURBEVOIE LAB (FR) | 2006-03-29 | — | — | CN | disclosed |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | NOVARTIS AG (CH) | 2005-04-28 | — | — | US | disclosed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |
| US-5861393-A | THROMBIN INHIBITORS; VASCULAR, CARDIOVASCULAR, NERVOUS SYSTEM AND BRAIN DISORDERS; ANTIISCHEMIC AND ANTIINFLAMMATORY AGENTS; RESTENOSIS | PFIZER INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5750520-A | SELECTIVE THROMBIN INHIBITORS; WOUND HEALING AGENTS | PFIZER INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0728132-B1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LTD (GB) | 1997-07-16 | — | — | EP | disclosed |
| EP-0728132-A1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LTD (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013274-A1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | COMT, TH, DDT | PPARA 1539/4885SYK 159/4885CTSS 987/4885 |
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | DAO, DDC, AADAT | PPARA 637/4885SYK 1953/4885CTSS 1408/4885 |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | PTPRS, PTPRJ, IRS1 | PPARA 1904/4885SYK 278/4885CTSS 1794/4885 |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | PTPRS, PTPMT1, PTPN1 | PPARA 2118/4885SYK 348/4885CTSS 1393/4885 |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | PTPRS, PTPA, PTPMT1 | PPARA 1848/4885SYK 160/4885CTSS 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.